Overview
Based on my prior experience in basic/translational immunology research and clinical hematopoietic stem cell transplantation, I am interested in early phase clinical protocols for novel immunotherapy of hematologic malignancies.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2019 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel.
Journal Article Br J Haematol · January 19, 2026 Full text Link to item CiteExploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.
Journal Article Transplant Cell Ther · January 2026 BACKGROUND: Chlorhexidine gluconate (CHG) bathing is recommended for infection prevention in hematopoietic cell transplantation (HCT) patients. As more centers transition HCT care to outpatient settings, understanding patients' perceptions of CHG bathing f ... Full text Link to item CiteSupplementary table from Associations between Alcohol Consumption Patterns and Risk of Multiple Myeloma: A Nationwide Cohort Study in South Korea
Other · November 26, 2025 Supplementary table from Associations between Alcohol Consumption Patterns and Risk of Multiple Myeloma: A Nationwide Cohort Study in South Korea ... Full text CiteRecent Grants
BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2022 - 2027Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2026A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2020 - 2024View All Grants
Education, Training & Certifications
Seoul National University (South Korea) ·
2002
M.D.